GKL-006

N/A

Report date: 2026/05/21 20:00:22

Base Information

Drug NameGKL-006
Drug Alias NameGKL-006GKL006GKL 006
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > NKT cell therapy > Invariant natural killer T cell therapyCell and gene therapy > Cell therapy > Donor > Autologous
Mechanisms of ActionGlypican-3 inhibitors
TargetsGlypican-3
Therapy Area/IndicationsPsoriasisPancreatic NeoplasmsLiver Neoplasms +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesBeijing Gene Key Life Technology Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesBeijing Gene Key Life Technology Co Ltd
Inactive CompaniesN/A
Active IndicationsPsoriasisPancreatic NeoplasmsLiver Neoplasms +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A